Skip to main content
. 2021 Jan 15;7:609322. doi: 10.3389/fmolb.2020.609322

Figure 4.

Figure 4

Subgroup analysis of OS. BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization; Sor, sorafenib; ICIs, immune checkpoint inhibitors; PFS, Progression-free survival; OS, overall survival.